REGRANEX (becaplermin) Gel

RW Johnson

Approval Status
Approved December 1997

Treatment for
diabetic foot ulcers

Dermatology / Plastic Surgery , Diabetes / Endocrinology

REGRANEX (becaplermin) Gel .01% has been approved for the treatment of diabetic foot ulcers that extend into the subcutaneous tissue or beyond, and have an adequate blood supply. This new topical gel, which contains genetically engineered platelet-derived growth factor, is the first prescription biologic that actively stimulates the body to grow new tissue to heal these wounds.

Clinical trials demonstrated that a once daily topical application of REGRANEX Gel plus good ulcer care healed more diabetic ulcers than placebo gel plus good ulcer care.

REGRANEX Gel was well tolerated in all clinical trials. Incidence of adverse events was similar in patients treated with REGRANEX, placebo gel, or good ulcer care alone.

The active ingredient in REGRANEX Gel is becaplermin, a genetically engineered platelet-derived growth factor that mimics a protein that occurs naturally in the body. The growth factor stimulates the migration of cells to the ulcer site, encouraging the patient's body to grow new tissue that heals these open wounds.

REGRANEX (becaplermin) Gel Drug Information

The REGRANEX (becaplermin) Gel drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top